• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    12/22/23 1:28:37 PM ET
    $ADN
    $AIR
    $ALLO
    $ALTR
    Industrial Machinery/Components
    Miscellaneous
    Aerospace
    Industrials
    Get the next $ADN alert in real time by email

    Shares of AAR Corp. (NYSE:AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

    AAR reported quarterly sales of $545.4 million, up 16% Y/Y, missing the consensus of $557.2 million. Adjusted EPS from continuing operations rose 17% Y/Y to 81 cents, beating the consensus of 80 cents.

    AAR recently disclosed the buyout of the Product Support business of Triumph Group Inc (NYSE:TGI) for $725 million.

    AAR shares fell 7% to $65.82 on Friday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • NextPlay Technologies, Inc. (NASDAQ:NXTP) shares jumped 263% to $3.29.
    • Jin Medical International Ltd. (NASDAQ:ZJYL) gained 71% to $120.50.
    • Daseke, Inc. (NASDAQ:DSKE) gained 64.8% to $8.10 after the company announced it will be acquired by TFI International.
    • Royalty Management Holding Corporation (NASDAQ:RMCO) jumped 59% to $3.18. Royalty Management Holding announced that Ferrox Holdings confirmed the commencement of production of titanium ferrite from its Tivani operating site.
    • Karuna Therapeutics, Inc. (NASDAQ:KRTX) shares gained 46.9% to $316.20. Bristol Myers Squibb & Co (NYSE:BMY) agreed to acquire Karuna Therapeutics for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
    • Polished.com Inc. (NYSE:POL) rose 46% to $5.91.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) jumped 40.8% to $5.92.
    • Argo Blockchain plc (NASDAQ:ARBK) gained 35% to $3.4801.
    • PureTech Health plc (NASDAQ:PRTC) climbed 33.8% to $24.95 after the company announced that its Founded Entity, Karuna Therapeutics, entered into a definitive merger agreement to be acquired by Bristol Myers Squibb.
    • Snow Lake Resources Ltd. (NASDAQ:LITM) rose 29.6% to $1.1389.
    • Asset Entities Inc. (NASDAQ:ASST) rose 25.9% to $0.8310 after jumping 45% on Thursday. Asset Entities, last month, announced a stock repurchase program.
    • Rocket Lab USA, Inc. (NASDAQ:RKLB) shares gained 25% to $5.54 after the company announced a new $515 million contract with a U.S. government customer.
    • Enlivex Therapeutics Ltd. (NASDAQ:ENLV) rose 23.6% to $2.8150. Enlivex Therapeutics recently announced that it completed enrollment of all 120 patients in its Phase II trial of Allocetra in patients with sepsis.
    • Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares rose 22.4% to $0.5466 after the company announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel.
    • Neumora Therapeutics, Inc. (NASDAQ:NMRA) surged 20.2% to $16.81.
    • Canaan Inc. (NASDAQ:CAN) gained 20% to $3.10.
    • Wheels Up Experience Inc. (NYSE:UP) rose 19.3% to $3.2801.
    • Bitdeer Technologies Group (NASDAQ:BTDR) gained 16.6% to $9.85.
    • MoneyLion Inc. (NYSE:ML) surged 14.6% to $64.42.
    • Tourmaline Bio, Inc. (NASDAQ:TRML) rose 14.3% to $23.01.
    • ALX Oncology Holdings Inc. (NASDAQ:ALXO) jumped 13.6% to $14.81.
    • Allogene Therapeutics, Inc. (NASDAQ:ALLO) gained 13.5% to $3.1333.
    • Mineralys Therapeutics, Inc. (NASDAQ:MLYS) rose 13% to $8.44. Mineralys said first subject dosed in Launch-HTN, the second pivotal trial of lorundrostat for treatment of hypertension.
    • ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) surged 11.5% to $11.71.
    • Jin Medical International Ltd. (NASDAQ:ZJYL) gained 11.5% to $78.62.
    • ImmunityBio, Inc. (NASDAQ:IBRX) shares rose 11.2% to $4.5350 after declining 10% on Thursday.
    • Apogee Therapeutics, Inc. (NASDAQ:APGE) jumped 10.3% to $28.17.
    • ANSYS, Inc. (NASDAQ:ANSS) gained 10.2% to $334.05.
    • Fulcrum Therapeutics, Inc. (NASDAQ:FULC) rose 10.2% to $6.36.
    • Prime Medicine, Inc. (NASDAQ:PRME) gained 9% to $9.55.
    • Compass, Inc. (NYSE:COMP) gained 8.7% to $3.50.
    • Altair Engineering Inc. (NASDAQ:ALTR) surged 8.3% to $80.95 after JP Morgan initiated coverage on the stock with an Overweight rating and $86 price target.

    Losers

    • AlloVir, Inc. (NASDAQ:ALVR) shares dipped 66.1% to $0.7904 after the company provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).
    • Jayud Global Logistics Limited (NASDAQ:JYD) fell 46% to $1.49.
    • Netcapital Inc. (NASDAQ:NCPL) shares fell 36% to $0.2114 after the company announced pricing of a $4 million public offering.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) shares fell 34.2% to $0.2050 after announcing a $2 million registered direct offering of common stock.
    • Banyan Acquisition Corporation (NYSE:BYN) fell 28.5% to $7.79.
    • ParaZero Technologies Ltd. (NASDAQ:PRZO) dipped 27% to $1.1700.
    • Linkage Global Inc (NASDAQ:LGCB) fell 24.4% to $1.77. Linkage Global recently priced $6 million initial public offering of 1.5 million ordinary shares at $4 per share.
    • Cemtrex, Inc. (NASDAQ:CETX) fell 20.3% to $5.18 following quarterly results.
    • ATIF Holdings Limited (NASDAQ:ATIF) dipped 20% to $0.8390.
    • Lottery.com Inc. (NASDAQ:LTRY) fell 18% to $3.01.The company’s shares jumped 196% on Thursday after the company announced an $18 million investment commitment from Prosperity Investment Management.
    • 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares fell 17.3% to $0.9103 after declining around 6% on Thursday.
    • Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) fell 17.1% to $2.9850 after the company announced a registered direct and private placement offering priced at-the-market under Nasdaq rules.
    • Brooge Energy Limited (NASDAQ:BROG) fell 16.4% to $3.3590.
    • Mullen Automotive, Inc. (NASDAQ:MULN) shares fell 15.9% to $11.98. Mullen Automotive shares jumped 78% on Thursday amid increased volatility following the company's 1-for-100 reverse split, and after the company announced 38 additional Class 3 vehicles have been delivered to Randy Marion Automotive Group with the company invoicing RMA for $2.5 million.
    • NetEase, Inc. (NASDAQ:NTES) fell 14.9% to $88.81 after China unveiled draft rules aimed at curbing spending on online gaming.
    • Nanobiotix S.A. (NASDAQ:NBTX) shares declined 13.8% to $6.62 after jumping more than 15% on Thursday.
    • NIKE, Inc. (NYSE:NKE) shares fell 10.8% to $109.31. NIKE posted better-than-expected earnings for its second quarter, but sales missed expectations. The company also stated that it is assessing opportunities to deliver up to $2 billion in cumulative cost savings during the next three years.
    • HUYA Inc. (NYSE:HUYA) shares declined 9.8% to $3.2750. HUYA entered into definitive agreement to acquire a global mobile application service provider.
    • Foot Locker, Inc. (NYSE:FL) declined 5.5% to $30.54. Shares of footwear and athletic apparel stocks traded lower in sympathy with Nike, which fell after reporting mixed second-quarter results, lowering its outlook and announcing cost savings plans.

     

    Now Read This: Ethereum Hits $2,300 Following PCE Data; Optimism Emerges As Top Gainer

    Get the next $ADN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADN
    $AIR
    $ALLO
    $ALTR

    CompanyDatePrice TargetRatingAnalyst
    Strive Inc.
    $ASST
    4/21/2026$36.00Buy
    H.C. Wainwright
    Allogene Therapeutics Inc.
    $ALLO
    4/16/2026Underweight → Neutral
    Analyst
    Nike Inc.
    $NKE
    4/13/2026$48.00Buy → Hold
    HSBC Securities
    Allogene Therapeutics Inc.
    $ALLO
    4/10/2026$6.00Buy
    Jefferies
    Strive Inc.
    $ASST
    4/10/2026$26.00Buy
    TD Cowen
    Nike Inc.
    $NKE
    4/10/2026$50.00Overweight → Neutral
    Piper Sandler
    Bitdeer Technologies Group
    $BTDR
    4/9/2026$10.00Overweight → Neutral
    Cantor Fitzgerald
    Rocket Lab Corporation
    $RKLB
    4/7/2026$85.00Mkt Perform → Mkt Outperform
    Citizens
    More analyst ratings

    $ADN
    $AIR
    $ALLO
    $ALTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance Yoshiyama Annie sold $22,144 worth of shares (9,586 units at $2.31), decreasing direct ownership by 7% to 124,517 units (SEC Form 4) to satisfy withholding tax

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    4/23/26 4:16:11 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by Hill Elliott

    4/A - NIKE, Inc. (0000320187) (Issuer)

    4/22/26 4:57:24 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    SEC Form 4 filed by Rodman David Malcom

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    4/21/26 6:59:35 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AIR
    $ALLO
    $ALTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AIR
    $ALLO
    $ALTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pham Benjamin bought $115,095 worth of shares (14,114 units at $8.15) (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/19/26 8:00:23 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Chief Legal Officer Beirne Brian Logan bought $100,387 worth of shares (11,500 units at $8.73), increasing direct ownership by 310% to 15,204 units (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/17/26 8:02:53 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AIR
    $ALLO
    $ALTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Strive with a new price target

    H.C. Wainwright initiated coverage of Strive with a rating of Buy and set a new price target of $36.00

    4/21/26 7:35:41 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Allogene upgraded by Analyst

    Analyst upgraded Allogene from Underweight to Neutral

    4/16/26 7:57:56 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NIKE downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded NIKE from Buy to Hold and set a new price target of $48.00

    4/13/26 8:43:38 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ADN
    $AIR
    $ALLO
    $ALTR
    SEC Filings

    View All

    SEC Form 6-K filed by ZIM Integrated Shipping Services Ltd.

    6-K - ZIM Integrated Shipping Services Ltd. (0001654126) (Filer)

    4/23/26 4:05:03 PM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    SEC Form DEFA14A filed by Prime Medicine Inc.

    DEFA14A - Prime Medicine, Inc. (0001894562) (Filer)

    4/23/26 8:38:03 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Prime Medicine Inc.

    DEF 14A - Prime Medicine, Inc. (0001894562) (Filer)

    4/23/26 8:35:02 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADN
    $AIR
    $ALLO
    $ALTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sports Entertainment Gaming Global Corporation Receives Expected Notice from The NASDAQ Stock Market LLC Pertaining to its Form 10-K of December 31, 2025

    FORT WORTH, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- On April 17, 2026, Sports Entertainment Gaming Global Corporation (NASDAQ:LTRY, LTRYW)) ("SEGG Media" or "the Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of not having timely filed the Form 10-K for the period ended December 31, 2025 with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires timely filing of all required periodic financial reports with the SEC. Additionally, the Notice indicated that under the Nasdaq Listing Rules, the Company may submit a plan to regain compliance with the Listing Rule w

    4/23/26 5:29:00 PM ET
    $LTRY
    $SEGG
    Computer Software: Prepackaged Software
    Technology

    Rocket Lab Unveils New High-Performance Star Tracker Optimized for Accuracy in Increased Radiation Environments

    LONG BEACH, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (NASDAQ:RKLB) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today announced its next-generation High-Performance Star Tracker (ST-HP), designed to improve key performance metrics for longer duration spacecraft missions in low Earth orbit and beyond. The High-Performance Star Tracker combines enhanced resilience with a targeted pointing accuracy of better than 1 arcsecond, ideal for missions where radiation tolerance is critical. The ST-HP's greater than 50 kRad, board-level Total Irradiation Dose ensures sustained attitude determination performance, maintaining precise sp

    4/23/26 4:15:00 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    BLDG Management Co., Inc.'s The Orchard Unveils The Arena, Professional-Grade Basketball Court Designed with NBA Skills Trainer Chris Brickley

    A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- BLDG Management Co., Inc., a full-service, vertically-integrated real estate investment, management and development firm, today unveiled The Arena at The Orchard, a professional-grade indoor basketball court designed in collaboration with world-renowned NBA Skills Trainer Chris Brickley. Situated within the tallest tower in Queens and Long Island City, the court sets a new benchmark for residential amenities, delivering a one-of-a-kind experience that combines pro-level design, advanced technology, and player-driven performance. The Arena marks the first

    4/23/26 11:00:00 AM ET
    $COMP
    EDP Services
    Technology

    $ADN
    $AIR
    $ALLO
    $ALTR
    Leadership Updates

    Live Leadership Updates

    View All

    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

    WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company. "I am thrilled to welcome Felecia as our new Chief Legal Officer," said Mik

    4/20/26 8:00:00 AM ET
    $ARDX
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Appoints Todd Violette as Chief Executive Officer

    BOSTON, MA, April 16, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a publicly traded fintech company that gives companies access to capital markets infrastructure without institutional-scale fees, today announced that its Board of Directors has appointed Mr. Violette to lead the Company in order to accelerate capital formation, expand platform reach, and build long-term shareholder value. Mr. Violette brings over 25 years of leadership experience across capital markets, fintech and digital asset-related businesses. His recent operating and executive roles have included CEO of CloudCover International, CEO of AppYea Inc., CEO of Vinergy, Chief Investment

    4/16/26 4:05:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

    CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine's financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. "We are delighted to welcome Svetlana to Prime Medicine," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. "Svetlana brings proven leadership at clinical-stage biotechnology companies, as well as deep capital markets experti

    4/16/26 8:00:00 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADN
    $AIR
    $ALLO
    $ALTR
    Financials

    Live finance-specific insights

    View All

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass, Inc. to Announce First Quarter Results on May 5

    NEW YORK, April 21, 2026 /PRNewswire/ -- Compass, Inc., d/b/a Compass International Holdings (the "Company") (NYSE:COMP), a global real estate services company, announced its first quarter 2026 financial results will be released after market close on Tuesday, May 5, 2026. The Company will host a conference call and webcast to discuss its results that afternoon at 5:00 p.m. ET / 2:00 p.m. PT. Call details are as follows:The conference call and shareholder presentation will be accessible online via the Company's Investor Relations website, https://investors.compass.com.You can als

    4/21/26 7:00:00 AM ET
    $COMP
    EDP Services
    Technology

    HUYA Inc. to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

    -Earnings Webinar Scheduled for 6:00 a.m. ET on May 12, 2026-GUANGZHOU, China, April 21, 2026 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE:HUYA), a leading game-related entertainment and services provider, today announced that it will report its first quarter 2026 unaudited financial results on Tuesday, May 12, 2026, before the open of U.S. markets. The Company's management will host a Tencent Meeting Webinar at 6:00 a.m. U.S. Eastern Time on May 12, 2026 (6:00 p.m. Beijing/Hong Kong time on May 12, 2026), to review and discuss the Company's business and financial performance.For participants who wish to join the webinar, please complete the online registration in advance using

    4/21/26 6:00:00 AM ET
    $HUYA
    Computer Software: Programming Data Processing
    Technology

    $ADN
    $AIR
    $ALLO
    $ALTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MoneyLion Inc.

    SC 13D/A - MONEYLION INC. (0001807846) (Subject)

    12/10/24 5:27:46 PM ET
    $ML
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13D/A filed by Rocket Lab USA Inc.

    SC 13D/A - Rocket Lab USA, Inc. (0001819994) (Subject)

    12/5/24 9:49:25 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13D/A filed by Rocket Lab USA Inc.

    SC 13D/A - Rocket Lab USA, Inc. (0001819994) (Subject)

    12/3/24 9:39:57 PM ET
    $RKLB
    Military/Government/Technical
    Industrials